ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

- Inflammasome ASC Inhibitor IC 100 designed to attenuate initiation and perpetuation of disease-causing inflammation; lead indication: obesity with metabolic complications (e.g., cardiovascular disease).

Read more at globenewswire.com